Zydus to sell cancer injection

Pharma major Zydus Cadila informed that the company has received the final approval from the US drug regulator to market Clonidine Hcl Injections. As per the announcement made by the company, the US Food and Drug Administration (USFDA) has given approval “to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.” Clonidine hydrochloride injection is a centrally acting analgesic solution for use in continuous epidural infusion devices which is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not relieved by opioid analgesics alone, the company statement said.